7,375 research outputs found
Recommended from our members
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.
Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)-many of which are refractory to current standard-of-care treatments-from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer
Challenges in identifying cancer genes by analysis of exome sequencing data.
Massively parallel sequencing has permitted an unprecedented examination of the cancer exome, leading to predictions that all genes important to cancer will soon be identified by genetic analysis of tumours. To examine this potential, here we evaluate the ability of state-of-the-art sequence analysis methods to specifically recover known cancer genes. While some cancer genes are identified by analysis of recurrence, spatial clustering or predicted impact of somatic mutations, many remain undetected due to lack of power to discriminate driver mutations from the background mutational load (13-60% recall of cancer genes impacted by somatic single-nucleotide variants, depending on the method). Cancer genes not detected by mutation recurrence also tend to be missed by all types of exome analysis. Nonetheless, these genes are implicated by other experiments such as functional genetic screens and expression profiling. These challenges are only partially addressed by increasing sample size and will likely hold even as greater numbers of tumours are analysed
Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients
BACKGROUND:
RNA sequencing data is providing abundant information about the levels of dysregulation of genes in various tumors. These data, as well as data based on older microarray technologies have enabled the identification of many genes which are upregulated in clear cell renal cell carcinoma (ccRCC) compared to matched normal tissue. Here we use RNA sequencing data in order to construct a panel of highly overexpressed genes in ccRCC so as to evaluate their RNA levels in whole blood and determine any diagnostic potential of these levels for renal cell carcinoma patients.
METHODS:
A bioinformatics analysis with Python was performed using TCGA, GEO and other databases to identify genes which are upregulated in ccRCC while being absent in the blood of healthy individuals. Quantitative Real Time PCR (RT-qPCR) was subsequently used to measure the levels of candidate genes in whole blood (PAX gene) of 16 ccRCC patients versus 11 healthy individuals. PCR results were processed in qBase and GraphPadPrism and statistics was done with Mann-Whitney U test.
RESULTS:
While most analyzed genes were either undetectable or did not show any dysregulated expression, two genes, CDK18 and CCND1, were paradoxically downregulated in the blood of ccRCC patients compared to healthy controls. Furthermore, LOX showed a tendency towards upregulation in metastatic ccRCC samples compared to non-metastatic.
CONCLUSIONS:
This analysis illustrates the difficulty of detecting tumor regulated genes in blood and the possible influence of interference from expression in blood cells even for genes conditionally absent in normal blood. Testing in plasma samples indicated that tumor specific mRNAs were not detectable. While CDK18, CCND1 and LOX mRNAs might carry biomarker potential, this would require validation in an independent, larger patient cohort
Recommended from our members
Identification of novel transcripts and peptides in developing murine lens.
We previously investigated the transcriptome and proteome profiles of the murine ocular lens at six developmental time points including two embryonic (E15 and E18) and four postnatal time points (P0, P3, P6, and P9). Here, we extend our analyses to identify novel transcripts and peptides in developing mouse lens. We identified a total of 9,707 novel transcripts and 325 novel fusion genes in developing mouse lens. Additionally, we identified 13,281 novel alternative splicing (AS) events in mouse lens including 6,990 exon skipping (ES), 2,447 alternative 3' splice site (A3SS), 1,900 alternative 5' splice site (A5SS), 1,771 mutually exclusive exons (MXE), and 173 intron retention (IR). Finally, we integrated our OMIC (Transcriptome and Proteome) datasets identifying 20 novel peptides in mouse lens. All 20 peptides were validated through matching MS/MS spectra of synthetic peptides. To the best of our knowledge, this is the first report integrating OMIC datasets to identify novel peptides in developing murine lens
Cancer cells exploit an orphan RNA to drive metastatic progression.
Here we performed a systematic search to identify breast-cancer-specific small noncoding RNAs, which we have collectively termed orphan noncoding RNAs (oncRNAs). We subsequently discovered that one of these oncRNAs, which originates from the 3' end of TERC, acts as a regulator of gene expression and is a robust promoter of breast cancer metastasis. This oncRNA, which we have named T3p, exerts its prometastatic effects by acting as an inhibitor of RISC complex activity and increasing the expression of the prometastatic genes NUPR1 and PANX2. Furthermore, we have shown that oncRNAs are present in cancer-cell-derived extracellular vesicles, raising the possibility that these circulating oncRNAs may also have a role in non-cell autonomous disease pathogenesis. Additionally, these circulating oncRNAs present a novel avenue for cancer fingerprinting using liquid biopsies
The identification of cell type defining genes across human tissues and the functional study of the endothelial adhesion G protein-coupled receptor L4
Cell type specific gene expression profiles underlie differences in cell morphology, behaviour, and specialized function. Single cell RNA sequencing can be used to measure gene expression in individual cells, but challenges remain including limited read-depth, artefactual changes due to dissociation from tissue, difficulties in the analysis of fragile or morphologically complex cell types, and bias introduced from the analysis of a limited number of biological replicates. In paper I, we used an integrative correlation analysis to define cell type enriched transcripts from bulk RNAseq, generated from visceral and subcutaneous adipose tissue. We identified depot and sex-specific differences. In Paper II, we expanded our analysis to include cell types in 15 human tissue types, to create a cell type enrichment prediction atlas for all protein coding genes. A cross-tissue comparison identified shared enrichment signatures between cell types in different tissues. We also defined core identity profiles of cell types present in all or most tissue types, including endothelial cells (EC), which can vary in gene enrichment profiles across different vascular beds. The focus of paper III was the functional characterisation of one such highly EC enriched gene, adhesion G protein-coupled rector L4 (ADGRL4). EC have a major role in various biological processes, including the regulation of inflammatory responses and haemostasis. The endothelial restricted expression of ADGRL4 is indicative of an important cell type specific role in EC. We depleted ADGRL4 in EC and measured associated changes in proteome and function, under normal and cytokine stimulated conditions. Under inflammatory conditions, ADGRL4 depletion potentiated EC pro-coagulant protein expression and associated thrombin and fibrin formation. Concurrently, ADGRL4 depletion inhibited the expression of inflammation-induced interferon response genes. This indicates that ADGRL4 has a currently unappreciated role in the EC function, with a potential role in the regulation of coagulation during inflammation
Transcriptome Sequencing for Precise and Accurate Measurement of Transcripts and Accessibility of TCGA for Cancer Datasets and Analysis
Next-generation sequencing (NGS) technologies are now well established and have become a routine analysis tool for its depth, coverage, and cost. RNA sequencing (RNA-Seq) has readily replaced the conventional array-based approaches and has become method of choice for qualitative and quantitative analysis of transcriptome, quantification of alternative spliced isoforms, identification of sequence variants, novel transcripts, and gene fusions, among many others. The current chapter discusses the multi-step transcriptome data analysis processes in detail, in the context of re-sequencing (where a reference genome is available). We have discussed the processes including quality control, read alignment, quantification of gene from read level, visualization of data at different levels, and the identification of differentially expressed genes and alternatively spliced transcripts. Considering the data that are freely available to the public, we also discuss The Cancer Genome Atlas (TCGA), as a resource of RNA-Seq data on cancer for selection and analysis in specific contexts of experimentation. This chapter provides insights into the applicability, data availability, tools, and statistics for a beginner to get familiar with RNA-Seq data analysis and TCGA
Recommended from our members
Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel.
The clinical benefits of the MammaPrint® signature for breast cancer is well documented; however, how these genes are related to cell cycle perturbation have not been well determined. Our single-cell transcriptome mapping (algorithm) provides details into the fine perturbation of all individual genes during a cell cycle, providing a view of the cell-cycle-phase specific landscape of any given human genes. Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel derived its clinical prognosis power from measuring the cell cycle activity of specific breast cancer samples. Such cell cycle phase index of the MammaPrint® signature suggested that measurement of the cell cycle index from tumors could be developed into a prognosis tool for various types of cancer beyond breast cancer, potentially improving therapy through targeting a specific phase of the cell cycle of cancer cells
- …